Elicio Therapeutics, Inc.: diluted weighted-average shares
Diluted weighted-average shares for Elicio Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Elicio Therapeutics, Inc. financial histories
What this measure means
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
Exact concept: us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2020-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Reading these values
This selected numerical history matches Basic weighted-average shares for the same reporting intervals and original units. The accounting definitions remain distinct. Equal values do not establish that the concepts are interchangeable or explain why they match; filing dates and accessions may differ. Compare the definitions and source filings before combining them.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 15,312,751 | shares | 2026-03-12 | 10-K · 0001601485-26-000027 |
| 2024-01-01 | 2024-12-31 | 12,202,996 | shares | 2026-03-12 | 10-K · 0001601485-26-000027 |
| 2023-01-01 | 2023-12-31 | 5,056,225 | shares | 2025-03-31 | 10-K · 0001601485-25-000049 |
| 2022-01-01 | 2022-12-31 | 315,998 | shares | 2024-03-29 | 10-K · 0001601485-24-000023 |
| 2021-01-01 | 2021-12-31 | 28,244,825 | shares | 2023-03-17 | 10-K · 0001601485-23-000011 |
| 2020-01-01 | 2020-12-31 | 14,762,120 | shares | 2022-03-30 | 10-K · 0001601485-22-000022 |
Related financial histories
- Elicio Therapeutics, Inc.: total assets
- Elicio Therapeutics, Inc.: total liabilities
- Elicio Therapeutics, Inc.: stockholders equity
- Elicio Therapeutics, Inc.: cash and cash equivalents
- Elicio Therapeutics, Inc.: net income or loss
- Elicio Therapeutics, Inc.: operating cash flow
- Elicio Therapeutics, Inc.: capital expenditure payments
- Elicio Therapeutics, Inc.: revenue
- Elicio Therapeutics, Inc.: financing cash flow
- Elicio Therapeutics, Inc.: investing cash flow
- Elicio Therapeutics, Inc.: retained earnings or deficit
- Elicio Therapeutics, Inc.: basic weighted-average shares
- Elicio Therapeutics, Inc.: basic earnings per share
- Elicio Therapeutics, Inc.: diluted earnings per share
- Elicio Therapeutics, Inc.: net property, plant and equipment
- Elicio Therapeutics, Inc.: share-based compensation expense
- Elicio Therapeutics, Inc.: operating income or loss
- Elicio Therapeutics, Inc.: current assets
- Elicio Therapeutics, Inc.: current liabilities
- Elicio Therapeutics, Inc.: current accounts payable
- Elicio Therapeutics, Inc.: cost of revenue
- Elicio Therapeutics, Inc.: research and development expense
Inspect the source
- Entity
- Elicio Therapeutics, Inc. / CIK 0001601485
- Captured
- 2026-09-20T09:25:24.218Z
- SEC response SHA-256
4658ce667672a29d8217f92b7294115160c0f599bb2841d4ee3a3278d5255354
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001601485.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))